Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451131 | 0.92 | NPC1 (0.52) | ALDH1A1RAB9ACXCR3LMNAPOLB | |
| SCHEMBL453737 | 0.89 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1NPSR1RAB9AMEN1 | |
| SCHEMBL447902 | 0.89 | PTGS2 (0.49) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL450061 | 0.89 | CXCR3 (0.54) | SMN1; SMN2ALDH1A1MEN1KMT2ACXCR3 | |
| SCHEMBL452947 | 0.89 | PIK3CD (0.47) | SMN1; SMN2ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL450044 | 0.86 | MEN1 (0.47) | SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL452172 | 0.86 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1NPSR1RAB9AMEN1 | |
| SCHEMBL1553362 | 0.86 | KCNH2 (0.44) | SMN1; SMN2ALDH1A1RAB9ATP53CXCR3 | |
| SCHEMBL1553219 | 0.85 | CXCR3 (0.52) | CXCR3 | |
| SCHEMBL448044 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1NPSR1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | claimed |
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2340838-A1 | Compositions and Methods of Treatment of Cancer | Minerva Biotechnologies Corporation (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-1425016-B1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1521746-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2003076418-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064025-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | SMN1; SMN2 4873/4885ALDH1A1 3161/4885NPSR1 388/4885 |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | SMN1; SMN2 4873/4885ALDH1A1 3161/4885NPSR1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.